Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an Australian, New Zealand and UK based service group, offering full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.

BioDesk is a team of in-house scientists and commercial drug development experts, who work closely with our clients from the earliest of planning stages. Together they create and manage Drug Development Plans, including all stages of pre-clinical/CMC programs that embrace global regulatory strategies whilst leveraging our unique regional advantage.

Australia and New Zealand have an outstanding product development timeline advantage due to our access to a pragmatic regulatory environment that makes it possible to add value to the global regulatory dossier and enter the clinic quickly, without the need for prior approval from another regulatory agency. Our clients have often established initial proof-of-concept quickly, and have enjoyed a time(cost) saving when compared to the more resource-intensive strategy of applying for an IND or CTA.

CNS has worked with clients whose cumulative acquisition price exceeds US$16.5billion; many of these clients initially fast-tracked their programs by running their phase 1 & 2 studies in Australia and New Zealand.

Further information on CNS can be found at www.clinical.net.au

Organisation type
Keywords
clinical trials
Mr Paul Cronin
Director, Business Development 
Ms Megan Hill
LinkedIn logo Business Development Manager 

Critical Pharmaceuticals

Organisation type
Dr Gareth King
CEO 

Sygnature Discovery

Integrated drug discovery - hit identification, lead generation and lead optimisation using medicinal chemistry, computational chemistry and in vitro biology. Through long-term strategic alliances we incorporate X-ray crystallography, ADME/tox, in vivo PK, and in vivo disease models. Experience across a wide range of disease areas, such as respiratory, oncology and CNS, and biological targets, e.g. kinases, GPCRs, PPIs, NHRs & epigenetics. Clients located in the USA, Europe and Australasia.

Organisation type
Keywords
chemical services
Dr Paul Clewlow
Senior Vice-President Business Development & Director